Nick James also on @Prof-Nick-James.bsky.social
@Prof_Nick_James
Followers
6K
Following
7K
Media
469
Statuses
5K
Professor of Prostate and Bladder Cancer Research. Interests: from novel diagnostics to care of advanced disease and novel trial design
London
Joined November 2012
RT @ProstateUKProfs: Could adding metformin to standard treatment help reduce side effects in men with advanced #ProstateCancer?. A team le….
0
8
0
RT @neerajaiims: Congrats @Prof_Nick_James & team👉@asco #ASCO25 👉a prognostic digital pathology based AI score (@arteraAI) identifies pts w….
0
30
0
RT @UrowebESU: In the context of #MIBC, is #TURBT still needed? 🔍 Some experts propose replacing it with sample biopsy. Ready for the debat….
0
5
0
Interesting, but needs to be benchmarked against schedules that include RT. Good long term function and durable high bladder preservation rates.
RETAIN-2 study shows promise for #BladderCancer preservation. @GhataliaPooja @FoxChaseCancer joins @UroDocAsh @MDAndersonNews to discuss the results and emphasizes that these results exceed previous chemo-immunotherapy combinations and highlight the importance of bladder
1
3
12
RT @GUresearch_MCR: @AshwinUrol presented metabolic outcomes data from the #STAMPEDE metformin trial demonstrating that the addition of met….
0
2
0
Very proud to collect this award on behalf of the huge team that makes up the STAMPEDE trial @MRCCTU staff, at least 3000 site staff and of course 12000 patients and their families. #teamscience.
Our third #NIHRImpactPrizes established investigator winner 🏆 is the STAMPEDE trial, for their multi arm platform trial to assess 10 different treatment approaches in men with advanced prostate cancer, leading to improvements in survival. Congratulations! The award was collected
9
7
50
RT @NIHRresearch: Our third #NIHRImpactPrizes established investigator winner 🏆 is the STAMPEDE trial, for their multi arm platform trial t….
0
9
0
Really interesting chat - how to design trials with injectables a challenging area. Also how to deal with issues like replication competent viruses in the COVID 19 conspiracy era touched upon!.
🎙 New Trials and Tribulations Podcast Episode with Prof Kevin Harrington, Head of Radiotherapy& Imaging @ICR_London and Consultant Oncologist @royalmarsdenNHS! . We delve into biological agents and clinical trials . 🎧 . @Prof_Nick_James @Hoda_Aty.
0
0
5
RT @Hoda_Aty: 🎙 New Trials and Tribulations Podcast Episode with Prof Kevin Harrington, Head of Radiotherapy& Imaging @ICR_London and Consu….
0
3
0
Our RADIO trial safety data on chemoRt- immunotherapy with durvalumab for muscle invasive bladder cancer from GU ASCO. In a nutshell - its safe and deliverable @CRCTU @ICR_London @VJOncology
0
2
8
Two interviews on the latest STAMPEDE data on topical oestrogen in place of standard ADT @ICR_London @MRCCTU. Teh second interview: Published by @VJOncology
0
0
4
Two interviews on the latest STAMPEDE data on topical oestrogen in place of standard ADT @ICR_London @MRCCTU . Published by @VJOncology
0
4
11
RT @AshwinUrol: Great to see the #STAMPEDE trial shortlisted for the @NIHRresearch Impact Prize 2025! 🏆. @MRCCTU @….
0
5
0
RT @urotoday: #Metformin study reveals weight management benefits for ADT therapy. @Silke_Gillessen and @neerajaiims discuss the results of….
0
9
0
Really powerful speech. We need to listen and act.
2
3
9
Latest from #STAMPEDE - intensified AR targeting drives increased prevalence of AR mutations at progression compared to monotherapy patient samples @MRCCTU @ICR_London @AttardLab.
1
14
31
Has indeed been a great meeting!.
#APCCCD @APCCC_Lugano . Great times with the incredible @Prof_Nick_James and @piet_ost . Wonderful debates, discussions of major trial gaps, learning the strengths weaknesses of each of our country’s health systems, and now I have a new podcast to listen to from @Prof_Nick_James.
0
0
19
RT @DrSpratticus: #APCCCD @APCCC_Lugano . Great times with the incredible @Prof_Nick_James and @piet_ost . Wonderful debates, discussions o….
0
7
0
RT @DrYukselUrun: Hormone intensification at ADT initiation increases AR alterations at progression! 🧬.In STAMPEDE, AR gene alterations wer….
0
25
0